Slide background

New level of antimicrobial efficacy

Slide background

Mul-1867 - inhaled antimicrobial being developed against multidrug-resistant infections in CF patients

Slide background

New level of antimicrobial efficacy

Who We Are & What We Do

The TGV-inhalonix is a biopharmaceutical company that is focused on the development of a first-in-class antibiotic to address unmet needs in lung infectious disease in cystic fibrosis patients in particular.

Learn more about TGV-inhalonix

Our Mission

We facilitate our efforts to bring to market our life-changing breakthroughs and to alleviate the suffering of patients affected by cystic fibrosis. We know that to make tomorrow happen for them is within our power.

Our Value Proposition

Recently granted Orphan Drug Designation by the U.S. Food and Drug Administration, Mul-1867, is the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi in cystic fibrosis patients.